Antiproliferative effects of selective adenosine receptor agonists and antagonists on human lymphocytes: Evidence for receptor-independent mechanisms

Purinergic Signalling

Volumn 9, Issue 3, 2013, Pages 351-365

  Schiedel, Anke C ^a   Lacher, Svenja K ^a   Linnemann, Carsten ^a   Knolle, Percy A ^a   Müller, Christa E ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

3H Thymidine incorporation; Adenosine receptors; Human lymphocytes; Jurkat T cells; Proliferation; Real time PCR; Receptor independent mechanisms

Indexed keywords

1 BUTYL 8 (3 NORADAMANTANYL) 3 (3 HYDROXYPROPYL)XANTHINE; 1 PROPYL 8 P SULFOPHENYLXANTHINE; 2 [6 AMINO 3,5 DICYANO 4 [4 (CYCLOPROPYLMETHOXY) PHENYL]PYRIDIN 2 YLSULFANYL]ACETAMIDE; 2 CHLORO N6 (3 IODOBENZYL) 9 [5 (METHYL CARBAMOYL) BETA D RIBOFURANOSYL] ADENINE; 2 P[2 CARBOXYETHYL]PHENETHYLAMINO) MINO) 5 , N ETHYLCARBOXAMIDOADENOSINE; 3 (3 HYDROXYPROPYL) 7 METHYL 8 (M METHOXYSTYRYL) 1 PROPARGYLXANTHINE; 5 N ETHYLCARBOXAMIDOADENOSINE; 6 N CYCLOPENTYLADENOSINE; 8 [4 [4 (4 CHLOROPHENYL)PIPERAZINE 1 SULFONYL)PHENYL]] 1 PROPYLXANTHINE; ADENOSINE A1 RECEPTOR; ADENOSINE A2A RECEPTOR; ADENOSINE A2B RECEPTOR; ADENOSINE RECEPTOR; ADENOSINE RECEPTOR BLOCKING AGENT; ADENOSINE RECEPTOR STIMULATING AGENT; BAY60 6583; CAFFEINE; DIMETHYL SULFOXIDE; MSX 2; PRELADENANT; PSB 10; PSB 36; R 8 ETHYL 4 METHYL 2 (2,3,5 TRICHLOROPHENYL) 1H IMIDAZO[2,1 I]PURIN 5 ONE; UNCLASSIFIED DRUG;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CELL CYCLE S PHASE; CELL DEATH; CELL ISOLATION; CELL PROLIFERATION; CELL STIMULATION; CONTROLLED STUDY; DNA SYNTHESIS; DOSE RESPONSE; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; NORMAL HUMAN; PERIPHERAL LYMPHOCYTE; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; T LYMPHOCYTE;

CELL PROLIFERATION; HUMANS; JURKAT CELLS; PURINERGIC P1 RECEPTOR AGONISTS; PURINERGIC P1 RECEPTOR ANTAGONISTS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, PURINERGIC P1; T-LYMPHOCYTES;

EID: 84883452068     PISSN: 15739538     EISSN: 15739546     Source Type: Journal    
DOI: 10.1007/s11302-013-9354-7     Document Type: Article

References (50)

1. Fredholm BB, IJzerman AP, Jacobson KA, Linden J, Müller CE (2011) International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors-an update. Pharmacol Rev 63(1): 1-34.
2. 2b adenosine receptors. Br J Pharmacol 122: 1075-1082.
3. Fredholm BB, IJzerman AP, Jacobson KA, Klotz KN, Linden J (2001) International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 53: 527-552.
4. Ernst PB, Garrison JC, Thompson LF (2010) Much ado about adenosine: adenosine synthesis and function in regulatory T cell biology. J Immunol 185(4): 1993-1998.
5. Linden J, Cekic C (2012) Regulation of lymphocyte function by adenosine. Arterioscler Thromb Vasc Biol 32(9): 2097-2103.
6. Ferrero ME (2011) Purinoceptors in inflammation: potential as anti-inflammatory therapeutic targets. Front Biosci 16: 2172-2186.
7. Burnstock G, Brouns I, Adriaensen D, Timmermans JP (2012) Purinergic signaling in the airways. Pharmacol Rev 64(4): 834-868.
8. 2A receptors directly inhibits IL-2 secretion in vitro and IL-2-driven expansion in vivo. Blood 105: 4707-4714.
9. 2 adenosine receptor-mediated immunosuppression. Br J Pharmacol 156: 297-306.
10. Barbieri D, Abbracchio MP, Salvioli S, Monti D, Cossarizza A, Ceruti S, Brambilla R, Cattabeni F, Jacobson KA, Franceschi C (1998) Apoptosis by 2-chloro-2′-deoxy-adenosine and 2-chloro-adenosine in human peripheral blood mononuclear cells. Neurochem Int 32: 493-504.
11. 2+-mediated mechanisms. Biochem J 304: 877-885.
12. Apasov SG, Sitkovsky MV (1999) The extracellular versus intracellular mechanisms of inhibition of TCR-triggered activation in thymocytes by adenosine under conditions of inhibited adenosine deaminase. Int Immunol 11: 179-189.
13. Desrosiers MD, Cembrola KM, Fakir MJ, Stephens LA, Jama FM, Shameli A, Mehal WZ, Santamaria P, Shi Y (2007) Adenosine deamination sustains dendritic cell activation in inflammation. J Immunol 179(3): 1884-1892.
14. Gelfand EW, Lee JJ, Dosch HM (1979) Selective toxicity of purine deoxynucleosides for human lymphocyte growth and function. Proc Natl Acad Sci U S A 76: 1998-2002.
15. Kizaki H, Suzuki K, Tadakuma T, Ishimura Y (1990) Adenosine receptor-mediated accumulation of cyclic AMP-induced T-lymphocyte death through internucleosomal DNA cleavage. J Biol Chem 265: 5280-5284.
16. 2B receptors. J Pharmacol Exp Ther 337(2): 444-450.
17. 3-mediated human glioblastoma cell proliferation. J Med Chem 53: 3954-3963.
18. Tanaka Y, Yoshihara K, Tsuyuki M, Kamiya T (1994) Apoptosis induced by adenosine in human leukemia HL-60 cells. Exp Cell Res 213: 242-252.
19. Abbracchio MP (1996) P1 and P2 receptors in cell growth and differentiation. Drug Dev Res 39: 393-406.
20. Jacobson KA, Hoffmann C, Cattabeni F, Abbracchio MP (1999) Adenosine-induced cell death: evidence for receptor-mediated signalling. Apoptosis 4: 197-211.
21. Mlejnek P, Dolezel P, Kosztyu P (2012) P-glycoprotein mediates resistance to A3 adenosine receptor agonist 2-chloro-N6-(3-iodobenzyl)-adenosine-5′-n-methyluronamide in human leukemia cells. J Cell Physiol 227: 676-685.
22. 3 adenosine receptor affects cell cycle progression and cell growth. Naunyn Schmiedebergs Arch Pharmacol 361: 225-234.
23. Merighi S, Mirandola P, Milani D, Varani K, Gessi S, Klotz KN, Leung E, Baraldi PG, Borea PA (2002) Adenosine receptors as mediators of both cell proliferation and cell death of cultured human melanoma cells. J Invest Dermatol 119: 923-933.
24. Panjehpour M, Karami-Tehrani F (2007) Adenosine modulates cell growth in the human breast cancer cells via adenosine receptors. Oncol Res 16: 575-585.
25. Schneider C, Wiendl H, Ogilvie A (2001) Biphasic cytotoxic mechanism of extracellular ATP on U-937 human histiocytic leukemia cells: involvement of adenosine generation. Biochim Biophys Acta 1538: 190-205.
26. 3 adenosine receptor as a new target for cancer therapy and chemoprotection. Exp Cell Res 269: 230-236.
27. 3 adenosine receptor activation inhibits cell proliferation via phosphatidylinositol 3-kinase/Akt-dependent inhibition of the extracellular signal-regulated kinase 1/2 phosphorylation in A375 human melanoma cells. J Biol Chem 280: 19516-19526.
28. 6-(2-isopentenyl)adenosine. Purinergic Signal 7: 453-462.
29. 2+ signal. Br J Pharmacol 145: 211-218.
30. 2B receptors. Am J Physiol Heart Circ Physiol 301(2): H391-401.
31. Merighi S, Benini A, Mirandola P, Gessi S, Varani K, Simioni C, Leung E, Maclennan S, Baraldi PG, Borea PA (2007) Caffeine inhibits adenosine-induced accumulation of hypoxia-inducible factor-1a, vascular endothelial growth factor, and interleukin-8 expression in hypoxic human colon cancer cells. Mol Pharmacol 72(2): 395-406.
32. 2B receptor modulates proliferation of colon carcinoma cells. Hum Pathol 41(11): 1550-1557.
33. Ceruti S, Franceschi C, Barbieri D, Malorni W, Camurri A, Giammarioli AM, Ambrosini A, Racagni G, Cattabeni F, Abbracchio MP (2000) Apoptosis induced by 2-chloro-adenosine and 2-chloro-2′-deoxy-adenosine in a human astrocytoma cell line: differential mechanisms and possible clinical relevance. J Neurosci Res 60: 388-400.
34. Minelli A, Bellezza I, Tucci A, Rambotti MG, Conte C, Culig Z (2009) Differential involvement of reactive oxygen species and nucleoside transporters in cytotoxicity induced by two adenosine analogues in human prostate cancer cells. Prostate 69: 538-547.
35. Mirabet M, Mallol J, Lluis C, Franco R (1997) Dipropylcyclopentylxanthine triggers apoptosis in Jurkat T cells by a receptor-independent mechanism. Cell Death Differ 4: 639-646.
36. 3 adenosine receptor activation. Cancer Biol Ther 7: 278-284.
37. Boyum A (1968) Separation of leukocytes from blood and bone marrow. Introduction. Scand J Clin Lab Invest Suppl 97: 7.
38. Pfaffl MW (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29: e45.
39. Ohta A, Sitkovsky M (2011) Methylxanthines, inflammation, and cancer: fundamental mechanisms. Handb Exp Pharmacol 200: 469-481.
40. + T lymphocytes against activation-induced cell death. FASEB J 24(8): 2631-2640.
41. 2A adenosine receptor signaling in lymphocytes and the central nervous system regulates inflammation during experimental autoimmune encephalomyelitis. J Immunol 188(11): 5713-5722.
42. 3 adenosine receptors in human lymphocytes: up-regulation in T cell activation. Mol Pharmacol 65(3): 711-719.
43. 2 adenosine receptors? Trends Immunol 26: 299-304.
44. Panjehpour M, Karami-Tehrani F (2004) An adenosine analog (IB-MECA) inhibits anchorage-dependent cell growth of various human breast cancer cell lines. Int J Biochem Cell Biol 36: 1502-1509.
45. Feng Y, Wu J, Feng X, Tao D, Hu J, Qin J, Li X, Xiao W, Gardner K, Judge SI, Li QQ, Gong J (2007) Timing of apoptosis onset depends on cell cycle progression in peripheral blood lymphocytes and lymphocytic leukemia cells. Oncol Rep 17: 1437-1444.
46. 2A receptors: a new strategy for basal ganglia disorders. Recent Pat CNS Drug Discov 2(1): 1-21.
47. Müller CE, Jacobson KA (2011) Recent developments in adenosine receptor ligands and their potential as novel drugs. Biochim Biophys Acta 1808(5): 1290-1308.
48. 6-ureidoadenosine derivatives. Bioorg Med Chem 20(2): 1008-1019.
49. Böhm L, Roos WP, Serafin AM (2003) Inhibition of DNA repair by Pentoxifylline and related methylxanthine derivatives. Toxicology 193(1-2): 153-160.
50. Garuti L, Roberti M, Bottegoni G (2009) Small molecule aurora kinases inhibitors. Curr Med Chem 16(16): 1949-1963.